clinical trial · NCT05221385
Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma
Changchun GeneScience Pharmaceutical Co., Ltd.·phase1·terminated·n = 58
Solid TumorNon-Hodgkin LymphomaGentulizumab
brief summary
The purpose of this study is to assess the safety and tolerability of gentulizumab, an anti-CD47 Monoclonal Antibody, in participants with solid tumors and non-Hodgkin lymphoma.
started
Apr 12, 2021
primary completion
May 30, 2023
completion
Oct 27, 2023
last updated
Nov 7, 2023
detailed description
This is a first-in-human, escalating dose trial of an antibody that inhibits an anti-apoptotic signal in human macrophages. The major aims of the study are to define the safety profile of this new drug, and to determine a recommended dose and schedule for potential additional trials.
official title
A Phase Ia, Open-label, Dose Escalation Study of Safety, Tolerability, Pharmacokinetics of Gentulizumab, an Anti-CD47 Monoclonal Antibody, in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma (NHL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol